Setmelanotide + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Prader-Willi Syndrome

Conditions

Prader-Willi Syndrome

Trial Timeline

Mar 19, 2015 → Oct 26, 2016

NCT ID

NCT02311673

About Setmelanotide + Placebo

Setmelanotide + Placebo is a phase 2 stage product being developed by Rhythm Pharmaceuticals for Prader-Willi Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02311673. Target conditions include Prader-Willi Syndrome.

What happened to similar drugs?

0 of 9 similar drugs in Prader-Willi Syndrome were approved

Approved (0) Terminated (1) Active (8)

🔄somatropin - GH naïve pediatric cohort + somatropin - GH treated cohort + somatropin - adult cohortPfizerPhase 3

🔄CarbetocinAcadia PharmaceuticalsPhase 3

🔄Carbetocin + PlaceboAcadia PharmaceuticalsPhase 3

🔄DCCRSoleno TherapeuticsPhase 3

🔄DCCR + DCCR + Placebo for DCCRSoleno TherapeuticsPhase 3

🔄PitolisantHarmony BiosciencesPhase 3

🔄Pitolisant tabletHarmony BiosciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06760546	Phase 3	Recruiting	Sep 23, 2025	Mar 13, 2028	Hypothalamic Obesity
NCT05774756	Phase 3	Active	Apr 26, 2023	Apr 16, 2027	Hypothalamic Obesity
NCT05093634	Phase 3	Active	Dec 10, 2021	Dec 31, 2026	Obesity
NCT04963231	Phase 2	Completed	Nov 30, 2021	Sep 30, 2024	Genetic Obesity
NCT03746522	Phase 3	Completed	Nov 23, 2018	Mar 8, 2021	Bardet Biedl Syndrome (BBS)
NCT03287960	Phase 3	Completed	Jan 30, 2018	Sep 25, 2020	Leptin Receptor Deficiency Obesity
NCT02896192	Phase 3	Completed	Feb 14, 2017	May 25, 2020	Pro-opiomelanocortin (POMC) Deficiency Obesity
NCT02311673	Phase 2	Completed	Mar 19, 2015	Oct 26, 2016	Prader-Willi Syndrome
NCT02041195	Phase 1/2	Completed	Jan 1, 2014	Dec 1, 2014	Overweight and Obesity
NCT01749137	Phase 2	Completed	Jan 14, 2013	Sep 28, 2013	Overweight

Competing Products

18 competing products in Prader-Willi Syndrome

See all competitors

Product	Company	Stage	Hype Score
Octreotide + Placebo	Novartis	Pre-clinical	18
Norditropin SimpleXx	Novo Nordisk	Pre-clinical	26
somatropin - GH naïve pediatric cohort + somatropin - GH treated cohort + somatropin - adult cohort	Pfizer	Phase 3	40
Setmelanotide	Rhythm Pharmaceuticals	Phase 2	36
RGH-706 + Placebo	Richter Gedeon	Phase 2	32
Carbetocin	Acadia Pharmaceuticals	Phase 3	44
Carbetocin + Placebo	Acadia Pharmaceuticals	Phase 3	41
DCCR	Soleno Therapeutics	Phase 3	38
DCCR + DCCR + Placebo for DCCR	Soleno Therapeutics	Phase 3	34
Pitolisant	Harmony Biosciences	Phase 3	41
Pitolisant tablet	Harmony Biosciences	Phase 3	41
Pitolisant oral tablets + Placebo oral tablet	Harmony Biosciences	Phase 2	33
DCCR	Soleno Therapeutics	Phase 3	26
VYKAT XR	Soleno Therapeutics	Pre-clinical	27
DCCR + Placebo for DCCR	Soleno Therapeutics	Phase 3	34
NNZ-2591	Neuren Pharmaceuticals	Phase 2	21
BMB-101 + Placebo	Bright Minds Biosciences	Phase 2	36
ARD-101	Aardvark Therapeutics	Phase 2	25